The Motley Fool

Stock market crash: I’d buy these 2 FTSE 100 shares in an ISA to get rich and retire early

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

The stock market crash has caused the FTSE 100 to trade around 20% down on the level at which it started the year. And further falls for the index cannot be ruled out either, due to the uncertain future for the world economy. But it means many FTSE members appear to offer sound business models that could deliver long-term growth at bargain prices.

As such, now could be the right time to buy them in a tax-efficient account such as an ISA while investor sentiment towards equities is relatively weak. With that in mind, here are two large-cap shares that could deliver high returns in the coming years and help you to retire early.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

FTSE 100 pharma stock AstraZeneca

AstraZeneca’s (LSE: AZN) recent quarterly trading update showed that it continues to deliver strong growth as it executes its strategy. The investment it has made in new medicines seems to be paying off, with the segment’s sales growing by 49%. This means that they now contribute almost half of the company’s total revenue. And it suggests that its overall growth rate could improve over the medium term.

Despite concerns about supply chain disruption caused by the coronavirus lockdown, investor sentiment towards the business has improved over recent months. For example, its shares have gained 11% since the start of the year. Few FTSE 100 companies are apparently able to offer the mix of defensive characteristics and growth potential of AstraZeneca. So sentiment towards the stock could continue to rise over the coming months.

Since global demand for healthcare products and services is likely to rise due to factors such as an ageing population, now could be the right time to buy a slice of AstraZeneca. It appears to offer strong growth prospects at a time when many industries are struggling to post rising bottom lines.


Another FTSE 100 company that appears to offer long-term growth potential is aerospace and defence business BAE (LSE: BA). Its recent trading update highlighted a number of contract wins over recent months. And this suggests that it may be faring better than a number of its index peers.

Looking ahead, BAE’s strong balance sheet could provide it with the financial means to maintain its dominant market position. It has access to a variety of borrowing options according to its recent update. And it may even be able to gain market share at the expense of competitors that do not have a financial position as strong as that of BAE.

With the company’s share price having fallen by 15% since the start of the year, it appears to offer a margin of safety. Although its trading conditions may deteriorate should government spending on defence come under pressure, it appears to offer long-term recovery potential due to its solid balance sheet and strong market position relative to sector peers.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Peter Stephens owns shares of AstraZeneca and BAE Systems. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.